Cargando…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
Autores principales: | Garrison, Louis P., Zamora, Bernarda, Li, Meng, Towse, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391119/ https://www.ncbi.nlm.nih.gov/pubmed/32223599 http://dx.doi.org/10.18553/jmcp.2020.26.4.400 |
Ejemplares similares
-
Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability
por: Watkins, John B., et al.
Publicado: (2020) -
The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia
por: Terris-Prestholt, Fern, et al.
Publicado: (2015) -
The cost-per-QALY threshold in England: Identifying structural uncertainty in the estimates
por: Zamora, Bernarda, et al.
Publicado: (2023) -
Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
por: Zamora, Bernarda, et al.
Publicado: (2021) -
Assessment of the effectiveness of supply-side cost-containment measures
por: Garrison, Louis P.
Publicado: (1992)